Skip to content
AlternativeMed

SPECIALTY TOPICS · GUIDE

Neurofeedback: Research Context

Neurofeedback trains people to change a brain-activity signal shown on a screen. This page reviews what controlled trials found for ADHD, pain and sleep, and what the FDA's biofeedback rule covers.

Content last updated . This page has not been medically reviewed.

Back to Emerging Wellness Science
Quick answer
Neurofeedback is a form of biofeedback. The device shows a person a signal from their own brain, usually an EEG trace, and the person tries to change it. The FDA's regulation defines a biofeedback device as an instrument that gives a visual or auditory signal tied to a body measure, such as brain alpha wave activity, so that the patient can control it voluntarily. [1] Nothing is sent into the brain. That separates it from the stimulation methods in electrical and magnetic stimulation basics.

The key question is whether learning to change a brain signal improves health. This page is information only, not medical advice. For consumer headbands and tracking, see the Biohacking guides, such as wearables and health trackers and brain optimization claims. For labels, see how we label evidence.

What research shows

5 findings · 1 supported · 1 mixed · 3 limited or unclearThe colour follows the evidence label on each card.
  1. ADHD

    No good evidence of benefit (as a group-level treatment)

    A 2025 meta-analysis of 38 randomized trials (2,472 participants aged 5 to 40) found no significant improvement in symptoms rated by people unaware of the treatment (standardized difference 0.04, 95% CI -0.10 to 0.18). [3]

  2. Chronic pain

    Promising but limited

    A 2020 review of 21 studies reported pain reductions, in one high-quality randomized trial and in most of the lower-quality studies. The authors call the evidence promising but largely low quality. [4]

  3. Insomnia and sleep quality

    No good evidence of benefit

    A 2024 meta-analysis found the control conditions improved sleep-quality scores more than the neurofeedback interventions. [5]

  4. Meditation with consumer EEG headbands

    Mixed

    A 2025 meta-analysis of 16 randomized trials found a small drop in distress but no evidence of improvement in cognition. [6]

  5. fMRI neurofeedback (brain scanner based)

    Insufficient evidence

    Authors of a 2025 review note that many articles and meta-analyses report symptom improvement, but that safety data are scarce and efficacy evidence in borderline personality disorder is limited. [7]

Depression and PTSD. Proper evidence not found. I searched PubMed for systematic reviews of EEG neurofeedback in depression and in post-traumatic stress disorder and did not find a usable review to read this session. This is a gap in what I checked, not proof of no effect.

ADHD in detail

ADHD has been studied the most. The 2025 meta-analysis counted a small benefit only in a subset of nine trials that used established standard protocols (standardized difference 0.21, 95% CI 0.02 to 0.40), and a small gain in processing speed with a wide range (0.35, 95% CI 0.01 to 0.69). [3] Results stayed similar when the analysis was limited to trials where learning to regulate the brain signal was shown. [3] The authors concluded that, at the group level, neurofeedback did not meaningfully benefit people with ADHD. [3]

A triple-blind trial in adults with ADHD compared real neurofeedback, sham neurofeedback and group therapy. Symptoms fell substantially in all groups, and neurofeedback was not superior to sham or to group therapy. [8] This shows why sham-controlled designs matter: improvement over time, attention from staff and expectation can look like a treatment effect.

A 2025 network meta-analysis in adults with ADHD also found that effects of non-drug approaches were inconsistent across raters. [9] Neurofeedback should not replace a clinician's evaluation or prescribed treatment, and no one should stop a medicine because of a neurofeedback course.

A changed signal is not an outcome

Neurofeedback trials can show that a person changed an EEG pattern. That shows learning of a skill, not that symptoms improved. The ADHD review is a clear example: even when trials showed the brain signal was regulated, group-level symptom benefit did not follow. [3] See clinical outcomes vs brain-signal changes.

How to evaluate a neurofeedback claim

  • Which condition, and which protocol, was tested? Results for one do not apply to others.
  • Was there a sham or other control group, and were raters unaware of the group?
  • Did symptoms improve, or only the brain signal?
  • Is the provider telling you to change medicines? Do not do that without your prescriber.

Related approaches with their own evidence are covered in heart-rate-variability biofeedback and breathing and do brain training games work.

Frequently asked questions

Is neurofeedback FDA approved?

The FDA regulates biofeedback devices as class II, and prescription battery-powered devices indicated for relaxation training and muscle reeducation are exempt from premarket notification. [1] The rule text I read does not list treatment of ADHD or other diseases. I did not check individual products.

Does neurofeedback work for ADHD?

A 2025 meta-analysis of randomized trials found no meaningful benefit overall when symptoms were rated by people unaware of the treatment. [3] A triple-blind adult trial found no advantage over sham. [8]

Can neurofeedback help chronic pain?

Reviews report pain reductions, but most evidence is low quality, so the label is promising but limited. [4]

Does it help with sleep?

In one meta-analysis, controls did better than neurofeedback on a sleep-quality score. [5]

Is a consumer EEG headband the same as clinical neurofeedback?

No. Consumer meditation headbands were studied separately and showed a small effect on distress but not on cognition. [6] Results from clinical protocols should not be applied to a different product.

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

Regulatory status (United States, read 2026-10-22)
The FDA rule for biofeedback devices places them in class II. It exempts battery-powered prescription devices from premarket notification when they are indicated for relaxation training and muscle reeducation. [1] The rule text I read does not name ADHD, depression or other conditions as cleared uses, so a claim that neurofeedback "treats" a disease needs its own regulatory record. I did not verify the record of any individual neurofeedback product.

Do not confuse it with a different FDA device type. The FDA's rule for an ADHD device describes a prescription device that stimulates through electrodes placed on the forehead. [2] That is nerve stimulation, not neurofeedback, and it does not support ADHD claims for neurofeedback.

Safety and who should check first
In the pain review, common side effects were headache, nausea and drowsiness. [4] No treatment-related serious adverse events were reported in the triple-blind ADHD trial. [8] I did not read device-specific warnings. People with seizure disorders or implanted devices should ask a clinician first. See brain stimulation contraindications and seizure considerations, which cover stimulation devices.
References
  1. Electronic Code of Federal Regulations. 21 CFR 882.5050, Biofeedback device. Read 2026-10-22.
  2. Electronic Code of Federal Regulations. 21 CFR 882.5898, Transcutaneous electrical nerve stimulator for attention deficit hyperactivity disorder. Read 2026-10-22.
  3. Westwood et al. Neurofeedback for Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA psychiatry, 2025. Read 2026-10-22.
  4. Patel et al. Effects of neurofeedback in the management of chronic pain: A systematic review and meta-analysis of clinical trials. European journal of pain (London, England), 2020. Read 2026-10-22.
  5. Recio-Rodriguez et al. Neurofeedback to enhance sleep quality and insomnia: a systematic review and meta-analysis of randomized clinical trials. Frontiers in neuroscience, 2024. Read 2026-10-22.
  6. Treves et al. Consumer-Grade Neurofeedback With Mindfulness Meditation: Meta-Analysis. Journal of medical Internet research, 2025. Read 2026-10-22.
  7. Paret et al. A randomised controlled trial of amygdala fMRI-neurofeedback versus sham-feedback in borderline-personality disorder - systematic literature review and introduction to the BrainSTEADy trial. BMC psychiatry, 2025. Read 2026-10-22.
  8. Schönenberg et al. Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial. The lancet. Psychiatry, 2017. Read 2026-10-22.
  9. Ostinelli et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The lancet. Psychiatry, 2025. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.